PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting taking place from 3 to 5 May 2023, in Mainz (Germany). The...
We are delighted to announce that our CEO will be presenting at the 6th Europe Neoantigen Summit 2023 hosted by Hanson Wade in Amsterdam (Netherlands) from April 24-26th! He will be presenting PDC...
We are very pleased to inform you about the publication of a new scientific paper in the peer-reviewed journal "Genes and Cancer" as a "Research Perspective". Article is entitled: Leveraging a...
We are very pleased to inform you about the publication of a new scientific article in the "International Journal of Molecular Sciences" in a special issue entitled "Dendritic Cell and Cancer Therapy...
Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab
Liège, Belgium, and Grenoble, France...
PDC*line Pharma will be presenting a poster at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress taking place from 7 to 9 December 2022, in Geneva, Switzerland...
We are delighted to announce that our CEO Eric Halioua will make a company presentation and will be panelist at the Finance and Investment track organized by Festival of Biologics in Basel on November...
We are delighted to announce that our CEO will be presenting at the Neoantigen-Based Therapies Summit 2022 hosted by Hanson Wade in Boston from October 24-26th! He will be presenting PDC*line Pharma...
Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer...
We are thrilled to announce that PDC*line Pharma will be presenting a poster at the ESMO - European Society for Medical Oncology Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris...
